Please Wait...


Abstract Submission and Topics

The abstract submission is closed


Abstract Submission
Each paper must not exceed 400 words, NO figures, tables and references will be accepted in the body of the abstract.
Only JPG files, up to 500KB, for images and tables can be uploaded.
The abstract will be structured in single headings: Introduction, Material and Methods, Results and Conclusion.

Abstract submission: Monday, October 4, 2021 – 09:00 CEST extended to Monday, October 11, 2021 – 09:00 CEST
Early bird registration fee: Sunday, December 12, 2021
Tentative notification to Authors: Monday, December 20, 2021

Encore Abstracts
Encore abstracts are admitted but it is not allowed to submit the very same abstract presented elsewhere. It is important to have at least a new aspect and/or analysis within more data or emphasis on different/additional interpretation.

Instructions to Authors
The corresponding author is responsible for the abstract. Please note that only the corresponding author will receive mail concerning the abstract and is responsible for informing all co-authors of the status of the abstract. The corresponding author can be a first author or not.
When the Scientific Committee will have evaluated all the received papers, the abstracts correspondents will receive all the information and necessary elements by mail.
Each abstract will be published as submitted. The organizers do not accept any responsibility for the accuracy of the abstracts.


  1. Pathogenesis (including autoantibodies)
  2. Pulmonary – Interstitial Lung Disease
  3. Pulmonay – Pulmonary Arterial Hypertension
  4. Cardiac
  5. Patient reported outcomes
  6. Quality of Life, Psychological & Social determinant of disease
  7. Vascular (including Raynaud’s and renal involvement)
  8. Imaging
  9. Musculoskeletal System & Rehabilitation
  10. Gastrointestinal involvement / Nutrition
  11. Gender-related Issues
  12. Recent Advances in established/approved therapies
  13. Paediatric Scleroderma
  14. Sclerosing skin diseases (including localized scleroderma)
  15. Emerging therapies (including pre-clinical studies)
  16. COVID-19-related topics
  17. Miscellaneous
  18. Case reports

For information about abstracts submission please contact:
AIM Group International – Rome Office
Via Flaminia 1068 – 00189 Rome, Italy
Tel. +39 06 33053313 – Fax +39 06 33053.249